Alemtuzumab

證據等級: L5

預測適應症: 10 個

Alemtuzumab: From B-Cell Chronic Lymphocytic Leukaemia to Syndrome with Combined Immunodeficiency

One-Sentence Summary

Alemtuzumab is a humanised anti-CD52 monoclonal antibody internationally approved for B-cell chronic lymphocytic leukaemia (B-CLL) and relapsing-remitting multiple sclerosis, but not currently registered in Denmark. The TxGNN model predicts it may be effective as a conditioning agent in allogeneic haematopoietic stem cell transplantation (allo-HSCT) for Syndrome with Combined Immunodeficiency, supported by 13 clinical trials and 12 publications. Note: the numerically highest TxGNN score belongs to hepatic infarction (94.44%), but this indication carries no supporting clinical evidence (L5, Hold); syndrome with combined immunodeficiency (93.73%) represents the most clinically actionable and evidence-supported prediction in this evidence pack.

Quick Overview

Item	Content
Original Indication	B-Cell Chronic Lymphocytic Leukaemia / Relapsing-Remitting Multiple Sclerosis (international approvals; no registered indication in Denmark)
Predicted New Indication	Syndrome with Combined Immunodeficiency
TxGNN Prediction Score	93.73%
Evidence Level	L3
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data are not available in the current evidence pack. Based on established pharmacological knowledge, Alemtuzumab is a humanised IgG1 kappa monoclonal antibody targeting CD52 — a glycoprotein highly expressed on mature T lymphocytes, B lymphocytes, NK cells, and monocytes. Upon binding CD52, it triggers rapid and sustained lymphocyte depletion via complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and direct apoptotic signalling, with minimal toxicity to non-haematopoietic tissues.

This lymphodepletion mechanism maps directly onto the requirements of allo-HSCT conditioning for combined immunodeficiency. Patients with primary combined immunodeficiency disorders — including SCID, XIAP deficiency, Hyper-IgM syndrome (CD40L deficiency), IPEX syndrome, Wiskott-Aldrich syndrome, and chronic granulomatous disease (CGD) — are characterised by absent or severely impaired lymphocyte function. Curative allo-HSCT in this setting requires immune space creation prior to transplant to permit donor cell engraftment while minimising graft-versus-host disease (GvHD) risk and transplant-related mortality. Alemtuzumab’s selective lymphocyte targeting, low organ toxicity, and suitability for reduced-intensity conditioning (RIC) make it particularly appropriate for fragile paediatric patients who cannot safely tolerate conventional myeloablative conditioning regimens.

The repurposing rationale is therefore a direct extension of the drug’s established pharmacology: the same CD52-targeting lymphodepletion used in treating lymphocytic malignancy is applied to immune-space creation for curative transplantation. Multiple specialist transplant centres internationally have incorporated alemtuzumab-based RIC as a standard conditioning backbone for paediatric primary immunodeficiency, and the available evidence base reflects established clinical practice rather than a speculative hypothesis. The primary evidence gap is the absence of Phase 3 RCTs, which reflects the rarity of these conditions rather than a fundamental pharmacological uncertainty.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00579137	Phase 1/2	Terminated	3	Only trial directly naming alemtuzumab as sole conditioning agent for allo-HSCT in SCID and primary immunodeficiency disorders; terminated early (3 patients enrolled), primary value is safety signal generation
NCT01182675	Phase 2	Terminated	7	Novel chemo-free conditioning using alemtuzumab + plerixafor/filgrastim for HSCT in children with SCID; aims to eliminate toxic chemotherapy conditioning while maximising T/B cell immune reconstitution
NCT05463133	Phase 1/2	Recruiting	50	Allo-HSCT for chronic granulomatous disease using alemtuzumab/busulfan/TBI combined with cytokine antagonists (IL-6 ± IFN-γ); largest ongoing trial directly incorporating alemtuzumab in a primary immunodeficiency
NCT07284641	Phase 2	Recruiting	25	RIC-HSCT with TBI for CVID and other autoimmune manifestations of primary immune regulatory disorders; most recently initiated prospective trial in this indication (2026 start)
NCT01652092	N/A	Active, not recruiting	57	Standard-of-care allo-HSCT guideline registry for primary immune deficiencies; largest real-world dataset in this indication, reflecting current clinical practice
NCT01962415	Phase 2	Recruiting	100	RIC with cord blood/bone marrow/PBSC transplant in paediatric and young adult non-malignant disorders including immunodeficiencies; largest active enrolment among ongoing trials
NCT01019876	Phase 2/3	Completed	38	Risk-adapted allo-SCT for non-malignant diseases including immunodeficiencies across four strata (bone marrow failure, immunodeficiencies, metabolic errors, histiocytoses); completed 2021 — long-term outcome data available
NCT01821781	Phase 2	Active, not recruiting	20	RIC-HSCT for immune function disorders using maximised host immunosuppression to reduce graft rejection; alemtuzumab likely included as conditioning component
NCT00744692	Phase 1	Completed	22	Feasibility of RIC in paediatric non-malignant disorder cord blood transplantation; earliest safety feasibility data in this population, engraftment endpoint >25% donor chimerism at 180 days
NCT04528355	N/A	Recruiting	50	Prospective outcomes registry for non-malignant disorders undergoing RIC-HSCT; specifically examines alemtuzumab dosing strata to prevent graft failure and support immune reconstitution

Literature Evidence

PMID	Year	Type	Journal	Key Findings
27543157	2016	Retrospective Cohort	Biol Blood Marrow Transplant	Single-centre comparison: alemtuzumab/fludarabine/melphalan RIC (n=4) vs myeloablative busulfan/cyclophosphamide/ATG (n=14) in CGD; RIC showed lower transplant-related toxicity
23131490	2013	Multicenter Retrospective	Blood	International survey of allo-HCT for XIAP deficiency (19 patients); alemtuzumab-based RIC predominated among 11 patients receiving reduced-intensity regimens; overall outcomes poor, highlighting unmet need
29155317	2018	Retrospective Cohort	Biol Blood Marrow Transplant	160 children with primary immunodeficiency receiving treosulfan/fludarabine/alemtuzumab conditioning; improved toxicity and T-cell chimerism compared to earlier cyclophosphamide-based cohort (n=70)
21325599	2011	Retrospective Cohort	Blood	70 children with primary immunodeficiency receiving treosulfan conditioning with alemtuzumab; lower veno-occlusive disease rates compared to busulfan; does not require pharmacokinetic monitoring
18940685	2008	Case Series	Biol Blood Marrow Transplant	Campath-1H (alemtuzumab) + fludarabine for rescue of stem cell graft failure in 12 paediatric patients including 4 with SCID; effective lymphodepletion achieved without myeloablation
26073206	2015	Single-Centre Retrospective	Pediatric Transplantation	HSCT outcomes for Hyper-IgM syndrome due to CD40L deficiency (5 patients, median age 41 months); HSCT demonstrated as curative in this combined immunodeficiency variant
19471859	2009	Case Series	Immunologic Research	FOXP3+ T-regulatory cell reconstitution after RIC-HSCT for IPEX syndrome; immune reconstitution of regulatory T cells correlated with clinical remission of multi-organ autoimmunity
11841458	2002	Case Report	Br J Haematol	Non-myeloablative BMT in a 26-year-old with Wiskott-Aldrich syndrome; alemtuzumab-based conditioning achieved partial engraftment and immune restoration despite active infections and vasculitis
15590388	2004	Safety Review	Haematologica	Infectious toxicity profile of alemtuzumab; key safety reference for its use in profoundly immunocompromised patients undergoing conditioning
18502831	2008	Case Report	Blood	EBV-positive lymphoproliferative disease following alemtuzumab-CHOP therapy; documents EBV reactivation risk with profound immunodepletion — critical safety signal for transplant setting

Denmark Market Information

Alemtuzumab currently has no national marketing authorisations registered with Lægemiddelstyrelsen (0 Danish registrations). Two alemtuzumab products hold or have held centralised EU marketing authorisations via the EMA, which apply in Denmark:

Authorisation Number	Product Name	Dosage Form	Approved Indication
EU/1/01/193 (marketing suspended)	MabCampath 30 mg/3 mL	Concentrate for solution for infusion	B-cell chronic lymphocytic leukaemia (first-line and relapsed/refractory); available via exceptional circumstances/compassionate use in EU
EU/1/13/878	Lemtrada 12 mg/1.2 mL	Concentrate for solution for infusion	Active relapsing-remitting multiple sclerosis in adults with ≥2 relapses in the preceding 2 years or rapidly evolving severe RRMS

Clinical use in Denmark for non-approved indications (e.g., conditioning for combined immunodeficiency) requires individual patient authorisation from Lægemiddelstyrelsen under named-patient or compassionate use provisions, or enrolment within an approved clinical trial protocol.

Cytotoxicity

Alemtuzumab carries antineoplastic approval (B-cell CLL). In the context of this repurposing evaluation, it functions as a targeted lymphodepleting conditioning agent rather than a direct tumour cytotoxic.

Item	Content
Cytotoxicity Classification	Targeted biological therapy — humanised anti-CD52 monoclonal antibody; lymphocyte-depleting; not a conventional cytotoxic agent
Myelosuppression Risk	Moderate — profound and prolonged lymphopenia (T, B, NK cell depletion); thrombocytopenia and neutropenia possible, particularly in combination with fludarabine/melphalan conditioning regimens
Emetogenicity Classification	Minimal to low (monoclonal antibody; primary acute toxicity is infusion-related reactions, not chemotherapy-type nausea/vomiting)
Monitoring Items	Full blood count with differential (CBC), lymphocyte subsets (CD3, CD4, CD8, CD19, CD56), CMV/EBV PCR (quantitative), renal function, liver function, thyroid function (long-term, for secondary autoimmunity), donor chimerism post-transplant
Handling Protection	Standard biological/monoclonal antibody handling procedures; not classified as a hazardous cytotoxic agent — standard aseptic precautions apply

Safety Considerations

Detailed SmPC warnings and contraindications are not available in the current evidence pack (blocking data gap — EMA SmPC for Lemtrada/MabCampath should be retrieved prior to prescribing). Based on published literature and known pharmacology:

Infectious toxicity: Profound and prolonged lymphopenia creates substantial risk for opportunistic infections including CMV reactivation, EBV-driven post-transplant lymphoproliferative disease, Pneumocystis jirovecii pneumonia, and invasive fungal infections; antimicrobial, antiviral, and antifungal prophylaxis is mandatory (PMID 15590388)
EBV-driven lymphoproliferation: Documented following alemtuzumab-induced immunodepletion; requires vigilant EBV PCR monitoring post-infusion (PMID 18502831)
Secondary autoimmunity: Well-documented after alemtuzumab in MS (immune thrombocytopenic purpura, autoimmune thyroid disease, anti-GBM nephropathy); relevance in the HSCT conditioning context requires monitoring for a minimum of 48 months post-infusion

Please refer to the approved Summary of Product Characteristics (SmPC) for Lemtrada and MabCampath for complete, current safety information before initiating treatment.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Alemtuzumab has a mechanistically sound and clinically documented role as a reduced-intensity conditioning agent in allo-HSCT for combined immunodeficiency, with a consistent evidence base across multiple Phase 1/2 trials and multicenter retrospective cohorts in paediatric populations where standard myeloablative conditioning carries unacceptable toxicity. The absence of Phase 3 RCT data reflects disease rarity rather than a fundamental evidence deficiency.

To proceed, the following is needed:

Mandatory — blocking: Retrieve complete SmPC safety data (warnings, contraindications, drug interactions) for Lemtrada/MabCampath from the EMA or Lægemiddelstyrelsen before formal safety evaluation can be completed
High priority: Obtain mechanism of action documentation from DrugBank (currently missing; affects mechanistic link analysis)
Regulatory: Apply for individual patient authorisation from Lægemiddelstyrelsen (named-patient basis), as alemtuzumab has no registered indication for immunodeficiency in Denmark
Clinical: Referral to a specialist paediatric haematology/immunology transplant centre for case-by-case assessment
Precision: Define the specific combined immunodeficiency subtype (SCID, CGD, XIAP, Hyper-IgM, IPEX, WAS, etc.) as conditioning intensity, donor selection, and risk-benefit profiles differ substantially across subtypes
Safety protocol: Establish pre-transplant infectious disease risk assessment and full prophylaxis protocol (CMV, EBV, PCP, invasive fungal) prior to conditioning initiation
Monitoring plan: Post-transplant immune reconstitution monitoring (lymphocyte subsets, donor chimerism) and long-term surveillance for secondary autoimmunity (minimum 48-month follow-up)

Note on hepatic infarction (TxGNN rank 1, score 94.44%): Although this indication received the numerically highest prediction score, it carries no clinical trial or literature support (Evidence Level L5). The high score likely reflects indirect topological connectivity in the knowledge graph (shared transplant complication nodes) rather than a direct causal pharmacological pathway. There is no known biological bridge between CD52-targeted lymphocyte depletion and vascular occlusive hepatic disease. Recommendation: Hold — no further evaluation warranted without new mechanistic evidence.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.